1. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target < 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78945 patients. Diabetes Obes Metab. 2012; 14(3): 228–33.
2. Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016; 121:17–26.
3. Tabak AG, Anderson J, Aschner P, Liu M, et al. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. Diabetes Ther. 2020; 11(1):305-318.
4. American Diabetes Association. Standards of Medical care in diabetes – 2018. Diabetes Care. 2018; 41(Suppl 1): S1–S159.
5. Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio coformulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019; 35(5): 793-804.
6. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8 :728–42.
7. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: A review of head to-head clinical studies. Ther Adv Endocrinol Metab. 2015; 6(1):19-28.
8. Blumer I, Pettus JH, Cavaiola TS. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgrad Med. 2018 ;130(4): 375-380.
9. Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type diabetes: A systematic review and meta – analysis. Diabetes Metab Res Rev. 2019; 35(1): e3082.
10. Buse J. Combining insulin and oral agents. Am J Med. 2000; 108 (Suppl 6a): 23s-32s.
11. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014; 8: 1335–51.
12. Giugliano D, Longo M, Caruso P, Fraia RD, et al. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care. 2021; 44(6): 1353-1360.
13. Yang Y, Chen S, Pan H, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials. Medicine. 2017; 96: 21 (e6944).